Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02566057 · ClinicalTrials.gov registry record · NA
Prospective Pharmacogenetic Testing and Clinical Outcomes in Patients With Early-Phase Psychosis
A NA study, sponsored by Northwell Health.
- Completed
- Registry status
- NA
- Development phase
- 36
- Enrollment target
NCT02566057: Completed NA study, sponsored by Northwell Health.
NCT02566057 is a NA study that has completed, run by Northwell Health. The registered enrollment target is 36 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02566057, a NA study, has completed, sponsored by Northwell Health.
- COMPLETED
- Registry status
- NA
- Development phase
- 36 participants
- Enrollment target
Study Summary
This study evaluates whether prospective pharmacogenetic testing is cost-effective in affecting clinical treatment outcomes in patients with early-phase psychosis.
Primary Outcome
Due to lack of efficacy or intolerability
Interventions
- BIOLOGICAL PGx testing guided treatment (PGT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2014-07-10 |
| Est. Completion | 2017-12-31 |
| Phase | NA |
What the finished NCT02566057 record still lists
NCT02566057 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which PGx testing guided treatment (PGT) is the first listed.
NCT02566057 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02566057 about?
NCT02566057 is a clinical study titled "Prospective Pharmacogenetic Testing and Clinical Outcomes in Patients With Early-Phase Psychosis". This study evaluates whether prospective pharmacogenetic testing is cost-effective in affecting clinical treatment outcomes in patients with early-phase psychosis.
What is the current status of trial NCT02566057?
This trial is currently completed. It is a NA study. The enrollment target is 36 participants. The study started on 2014-07-10. Estimated completion is 2017-12-31.
What interventions are being tested in trial NCT02566057?
The interventions under investigation include: PGx testing guided treatment (PGT) (BIOLOGICAL).
Who is sponsoring clinical trial NCT02566057?
This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02566057's enrollment target sits among peer trials
36 1541st of 2000 higher than 437 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI